Glenmark Pharma secures US FDA nod for Fluticasone Nasal Spray
Glenmark Pharmaceuticals received US FDA approval on August 20, 2026, for Fluticasone Propionate Nasal Spray USP, 0.05 mg/spray, bioequivalent to Flonase® Nasal Spray by Haleon US Holdings LLC [NDA 020121]. The addressable market for the reference drug stood at approximately $295.2 million in annual sales for the 12 months ending June 2026, per IQVIA® data. Glenmark Pharmaceuticals Inc., USA will distribute the product in the US market.
*this image is generated using AI for illustrative purposes only.
Glenmark Pharmaceuticals received approval from the US Food and Drug Administration (FDA) for its Fluticasone Propionate Nasal Spray USP, 0.05 mg/spray. The company announced the regulatory milestone on August 20, 2026, marking an expansion of its respiratory portfolio in the United States.
The approved product is bioequivalent and therapeutically equivalent to the reference listed drug, Flonase® Nasal Spray, 0.05 mg/spray, manufactured by Haleon US Holdings LLC [NDA 020121]. Glenmark Pharmaceuticals Inc., USA will handle the distribution of the nasal spray in the US market. The FDA approval is limited to the indications listed in Glenmark's approved label, which may differ from the approved indications of the reference listed drug.
Market context
According to IQVIA® sales data for the 12 months ending June 2026, the total market for Flonase® Nasal Spray, including brand and all available therapeutic equivalents, achieved annual sales of approximately $295.2 million. The table below summarises the key details of the approved product.
| Parameter: | Details |
|---|---|
| Product: | Fluticasone Propionate Nasal Spray USP, 0.05 mg/spray |
| Reference drug: | Flonase® Nasal Spray, 0.05 mg/spray |
| Reference NDA: | NDA 020121 |
| Manufacturer of reference drug: | Haleon US Holdings LLC |
| US distributor: | Glenmark Pharmaceuticals Inc., USA |
| Addressable market (annual): | $295.2 million |
| Market data period: | 12 months ending June 2026 |
| Market data source: | IQVIA® |
What the numbers show
With the reference drug commanding approximately $295.2 million in annual sales, Glenmark's entry targets a well-established segment within respiratory care. The approval positions the company to compete through price competitiveness, a standard dynamic in the generic pharmaceuticals sector.
Executive commentary
Marc Kikuchi, President and Business Head for North America at Glenmark, stated that the approval builds on the strong foundation the company has established in the respiratory therapeutic area. He emphasised the company's commitment to broadening access to quality, affordable treatment options for patients and healthcare providers.
Historical Stock Returns for Glenmark Pharmaceuticals
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +1.30% | -0.63% | +1.61% | +12.84% | +16.95% | +321.60% |
How might Glenmark's pricing strategy for this generic Fluticasone Propionate Nasal Spray impact Haleon's market share in the $295.2 million addressable market?
What is the expected timeline for Glenmark to achieve significant sales volume given the existing competition from other therapeutic equivalents?
How does this approval align with Glenmark's broader pipeline strategy for expanding its respiratory portfolio in the US over the next 12 to 24 months?
20
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
